These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
143 related items for PubMed ID: 38890407
1. Analysis of MDM2 and TP53 genes in canine liposarcoma. Muscatello LV, de Biase D, Maloberti T, di Oto E, Tallini G, Pellegrino V, Bacci B, Roccabianca P, Lepri E, Crippa L, Avallone G. Sci Rep; 2024 Jun 18; 14(1):14087. PubMed ID: 38890407 [Abstract] [Full Text] [Related]
2. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, Rao S, Pasquini G, Azzarelli A, Rilke F, Pierotti MA. J Pathol; 1997 Jan 18; 181(1):14-24. PubMed ID: 9071998 [Abstract] [Full Text] [Related]
3. p53 Expression in Canine Liposarcoma Correlates With Myxoid Variant and Higher Proliferative Activity. Avallone G, Muscatello LV, Leoni A, Roccabianca P, Lepri E, Crippa L, Bacci B. Vet Pathol; 2020 Sep 18; 57(5):620-622. PubMed ID: 32744152 [Abstract] [Full Text] [Related]
4. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma. Avallone G, Roccabianca P, Crippa L, Lepri E, Brunetti B, Bernardini C, Forni M, Olandese A, Sarli G. Vet Pathol; 2016 Jul 18; 53(4):773-80. PubMed ID: 26993784 [Abstract] [Full Text] [Related]
7. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S. Lab Invest; 2013 Nov 18; 93(11):1232-40. PubMed ID: 24018792 [Abstract] [Full Text] [Related]
8. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall. Kuczkiewicz-Siemion O, Wiśniewski P, Dansonka-Mieszkowska A, Grabowska-Kierył M, Olszewska K, Goryń T, Prochorec-Sobieszek M, Rutkowski P, Szumera-Ciećkiewicz A. Pathol Res Pract; 2021 Sep 18; 225():153555. PubMed ID: 34325315 [Abstract] [Full Text] [Related]
11. [Myxiod pleomorphic liposarcoma: a clinicopathological and molecular genetic analysis of six cases]. Zheng XC, Huang HJ, You J, Lin XY, Chen DR, Zhong D. Zhonghua Bing Li Xue Za Zhi; 2022 Aug 08; 51(8):738-742. PubMed ID: 35922164 [Abstract] [Full Text] [Related]
12. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection. Butò S, Pierotti MA, Tamborini E, Della Torre G, Lavarino C, Rilke F, Pilotti S. Diagn Mol Pathol; 1999 Sep 08; 8(3):125-30. PubMed ID: 10565683 [Abstract] [Full Text] [Related]
18. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, Rubin BP, Skacel M. Mod Pathol; 2008 Aug 08; 21(8):943-9. PubMed ID: 18500263 [Abstract] [Full Text] [Related]
19. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. Segura-Sánchez J, González-Cámpora R, Pareja-Megia MJ, García-Escudero A, Galera-Ruiz H, López-Beltrán A. Anticancer Res; 2006 Aug 08; 26(6C):4937-42. PubMed ID: 17214366 [Abstract] [Full Text] [Related]
20. FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations. Gambella A, Bertero L, Rondón-Lagos M, Verdun Di Cantogno L, Rangel N, Pitino C, Ricci AA, Mangherini L, Castellano I, Cassoni P. Int J Mol Sci; 2023 Jan 10; 24(2):. PubMed ID: 36674856 [Abstract] [Full Text] [Related] Page: [Next] [New Search]